BOLDBoundless Bio, Inc.

$26M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$1M

Operating Income

-$73M

Net Income

-$65M

EPS (Diluted)

$-3.85

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$63M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$206M

Total Liabilities

$56M

Stockholders' Equity

$151M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$1M	$0	—
Operating Income	-$73M	-$55M	-33.7%
Net Income	-$65M	-$49M	-32.2%

BOLD FY 2024 Earnings — Boundless Bio, Inc. Revenue & Financial Results | Market Cap Arena